keyword
MENU ▼
Read by QxMD icon Read
search

decompensated heart failure

keyword
https://www.readbyqxmd.com/read/29149013/confounders-affecting-the-prognosis-in-patients-with-acute-decompensated-heart-failure-who-underwent-extracorporeal-membrane-oxygenation
#1
Michihito Kyo, Shinichiro Ohshimo, Nobuaki Shime
No abstract text is available yet for this article.
December 2017: Critical Care Medicine
https://www.readbyqxmd.com/read/29142540/clinical-audit-of-dengue-related-deaths-in-2011-mayo-hospital-lahore-pakistan
#2
Somia Iqtadar, Nabeel Akbar, Mehreen Mehmood, Sajid Abaidullah
Background and Objective: Dengue infection has evolved into an epidemic during last few years in Pakistan and has been associated with poor outcomes. Literature with respect to mortality risk factors in Dengue infection is not sufficient. This compelled us to conduct this study to find out major contributory factors to death in patients with dengue viral infection at one of Asia's ancient hospital setting with an aim to recognize complications at earliest and improve case management in future...
September 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29141964/acute-decompensated-pulmonary-hypertension
#3
Laurent Savale, Jason Weatherald, Xavier Jaïs, Constance Vuillard, Athénaïs Boucly, Mitja Jevnikar, David Montani, Olaf Mercier, Gerald Simonneau, Elie Fadel, Olivier Sitbon, Marc Humbert
Acute right heart failure in chronic precapillary pulmonary hypertension is characterised by a rapidly progressive syndrome with systemic congestion resulting from impaired right ventricular filling and/or reduced right ventricular flow output. This clinical picture results from an imbalance between the afterload imposed on the right ventricle and its adaptation capacity. Acute decompensated pulmonary hypertension is associated with a very poor prognosis in the short term. Despite its major impact on survival, its optimal management remains very challenging for specialised centres, without specific recommendations...
December 31, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29141858/interleukin-1-blockade-in-recently-decompensated-systolic-heart-failure-results-from-redhart-recently-decompensated-heart-failure-anakinra-response-trial
#4
Benjamin W Van Tassell, Justin Canada, Salvatore Carbone, Cory Trankle, Leo Buckley, Claudia Oddi Erdle, Nayef A Abouzaki, Dave Dixon, Dinesh Kadariya, Sanah Christopher, Aaron Schatz, Jessica Regan, Michele Viscusi, Marco Del Buono, Ryan Melchior, Pranav Mankad, Juan Lu, Robin Sculthorpe, Giuseppe Biondi-Zoccai, Edward Lesnefsky, Ross Arena, Antonio Abbate
BACKGROUND: An enhanced inflammatory response predicts worse outcomes in heart failure (HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF. METHODS AND RESULTS: We randomly assigned 60 patients with reduced left ventricular ejection fraction (<50%) and elevated C-reactive protein levels (>2 mg/L), within 14 days of hospital discharge, to daily subcutaneous injections with anakinra 100 mg for 2 weeks, 12 weeks, or placebo...
November 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29131282/prognostic-value-of-daytime-heart-rate-blood-pressure-their-products-and-quotients-in-chronic-heart-failure
#5
Anna Kowalczys, Michał Bohdan, Marcin Gruchała
BACKGROUND: Chronic heart failure (CHF) is an important epidemiological and therapeuthic issue with poor prognosis. The aim of the study was to estimate the prognostic value of daytime heart rate (HR), blood pressure (BP), their products and quotients in patients with CHF. METHODS: The study included 80 stable patients with CHF and reduced left ventricular ejection fraction (LVEF ≤ 35%). Physical examination, laboratory blood tests, electrocardiogram, chest X-ray, echocardiography, 6-minute walk test (6MWT), telemetry monitoring and BP measurements were performed in all participants...
November 13, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/29128961/the-relationship-between-the-time-until-commencement-of-tolvaptan-and-the-length-of-hospital-stay-in-heart-failure-patients
#6
Shunsuke Kiuchi, Shinji Hisatake, Takayuki Kabuki, Takashi Oka, Shintaro Dobashi, Takahiro Fujii, Takanori Ikeda
The effect of early use of tolvaptan (TLV) for acute decompensated heart failure (ADHF) is unclear. We investigated the relationship between early use of TLV and the length of hospital stay. 369 consecutive ADHF patients who received TLV during hospitalization between February 2011 and June 2016 were initially enrolled. Patients who died in hospital, transferred hospital or clinical scenario 4 or 5 were excluded. We analyzed 247 ADHF patients. We evaluated the relationship between the length of hospital stay and the following findings: blood pressures, heart rate, New York Heart Association classification, and blood tests on admission...
November 11, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/29118765/urinary-liver-type-fatty-acid-binding-protein-level-as-a-predictive-biomarker-of-acute-kidney-injury-in-patients-with-acute-decompensated-heart-failure
#7
Keiichi Hishikari, Hiroyuki Hikita, Shun Nakamura, Shun Nakagama, Masahumi Mizusawa, Tasuku Yamamoto, Junichi Doi, Yosuke Hayashi, Yuya Utsugi, Makoto Araki, Yuta Sudo, Shigeki Kimura, Atsushi Takahashi, Takashi Ashikaga, Mitsuaki Isobe
Background: There are no biological markers to predict the onset of acute kidney injury (AKI) in patients with acute decompensated heart failure (ADHF). Liver-type fatty acid-binding protein (L-FABP) levels are markedly upregulated in the proximal tubules after renal ischemia. We investigated whether urinary L-FABP is a suitable marker to predict AKI in ADHF patients. Methods: We examined 281 consecutive patients with ADHF. Serum creatinine (Cr) and L-FABP levels were measured at admission and 24 and 48 h after admission...
October 2017: Cardiorenal Medicine
https://www.readbyqxmd.com/read/29106648/validation-of-echocardiographic-criteria-for-the-clinical-diagnosis-of-heart-failure-in-chronic-kidney-disease
#8
Kathrin Untersteller, Sarah Seiler-Mußler, Francesca Mallamaci, Danilo Fliser, Gérard M London, Carmine Zoccali, Gunnar H Heine
Background: The Acute Dialysis Quality Initiative (ADQI) XI Workgroup has suggested defining heart failure (HF) in patients with end-stage renal disease by the presence of at least one out of eight predefined echocardiographic criteria. Given the high prevalence of echocardiographic alterations in chronic kidney disease (CKD) patients, we hypothesized that application of echocardiographic ADQI criteria will result in overdiagnosis of HF, without providing substantial prognostic information...
July 5, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29098525/prognostic-value-of-real-time-three-dimensional-echocardiography-compared-to-two-dimensional-echocardiography-in-patients-with-systolic-heart-failure
#9
Frederico J N Mancuso, Valdir A Moises, Dirceu R Almeida, Dalva Poyares, Luciana J Storti, Flavio S Brito, Sergio Tufik, Angelo A V de Paola, Antonio C C Carvalho, Orlando Campos
Heart failure (HF) is associated with morbidity and mortality. Real-time three-dimensional echocardiography (RT3DE) may offer additional prognostic data in patients with HF. The study aimed to evaluate the prognostic value of real-time three-dimensional echocardiography (RT3DE). This is a prospective study that included 89 patients with HF and left ventricular ejection fraction (LVEF) < 0.50 who were followed for 48 months. Left atrium and ventricular volumes and functions were evaluated by RT3DE. TDI and two-dimensional echocardiography parameters were also obtained...
November 2, 2017: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/29092550/acoustic-speech-analysis-of-patients-with-decompensated-heart-failure-a-pilot-study
#10
Olivia M Murton, Robert E Hillman, Daryush D Mehta, Marc Semigran, Maureen Daher, Thomas Cunningham, Karla Verkouw, Sara Tabtabai, Johannes Steiner, G William Dec, Dennis Ausiello
This pilot study used acoustic speech analysis to monitor patients with heart failure (HF), which is characterized by increased intracardiac filling pressures and peripheral edema. HF-related edema in the vocal folds and lungs is hypothesized to affect phonation and speech respiration. Acoustic measures of vocal perturbation and speech breathing characteristics were computed from sustained vowels and speech passages recorded daily from ten patients with HF undergoing inpatient diuretic treatment. After treatment, patients displayed a higher proportion of automatically identified creaky voice, increased fundamental frequency, and decreased cepstral peak prominence variation, suggesting that speech biomarkers can be early indicators of HF...
October 2017: Journal of the Acoustical Society of America
https://www.readbyqxmd.com/read/29082629/aetiology-timing-and-clinical-predictors-of-early-vs-late-readmission-following-index-hospitalization-for-acute-heart-failure-insights-from-ascend-hf
#11
EDITORIAL
Marat Fudim, Christopher M O'Connor, Allison Dunning, Andrew P Ambrosy, Paul W Armstrong, Adrian Coles, Justin A Ezekowitz, Stephen J Greene, Marco Metra, Randall C Starling, Adriaan A Voors, Adrian F Hernandez, G Michael Felker, Robert J Mentz
AIMS: Patients hospitalized for heart failure (HF) are at high risk for 30-day readmission. This study sought to examine the timings and causes of readmission within 30 days of an HF hospitalization. METHODS AND RESULTS: Timing and cause of readmission in the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure) trial were assessed. Early and late readmissions were defined as admissions occurring within 0-7 days and 8-30 days post-discharge, respectively...
October 29, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29079391/strategies-for-supporting-intervention-fidelity-in-the-rehabilitation-therapy-in-older-acute-heart-failure-patients-rehab-hf-trial
#12
Amy M Pastva, Pamela W Duncan, Gordon R Reeves, M Benjamin Nelson, David J Whellan, Christopher M O'Connor, Joel D Eggebeen, Leigh Ann Hewston, Karen M Taylor, Robert J Mentz, Paul B Rosenberg, Dalane W Kitzman
INTRODUCTION: Acute decompensated heart failure (ADHF) is the leading cause of hospitalization in older adults. Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial is a multi-site clinical trial to determine if physical rehabilitation intervention in older patients with ADHF improves physical function and reduces rehospitalizations. The REHAB-HF intervention aims to improve functional performance utilizing reproducible and progressive exercises that are individually tailored to the patient's physiological and physical capabilities...
October 24, 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29076180/a-rare-case-of-subcommissural-adhesive-aortic-stenosis-triangular-struggle-of-aortic-valve-area-hemodynamics-and-calcium-burden
#13
Hiroki Matsuzoe, Kensuke Matsumoto, Shumpei Mori, Takayoshi Toba, Hiroyuki Kawamori, Shinsuke Shimoyama, Hidekazu Tanaka, Toshiro Shinke, Ken-Ichi Hirata
This report concerns an 83-year-old woman with aortic stenosis (AS) who had a history of repetitive hospitalization due to decompensated heart failure. Although her clinical history was compatible with significant AS, findings for aortic valve area, hemodynamics, and valvular calcium burden were discrepant. Multiplanar reconstruction images revealed the membranous structures attached to a subcommissural lesion, which resulted in severe stenosis. The patient had a favorable clinical course after transcatheter aortic valve replacement...
October 27, 2017: Echocardiography
https://www.readbyqxmd.com/read/29074419/should-hemodynamic-guidance-for-treatment-of-acute-decompensated-heart-failure-be-driven-by-the-right
#14
EDITORIAL
Joseph A Franciosa
No abstract text is available yet for this article.
October 23, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29056460/use-of-a-percutaneous-temporary-circulatory-support-device-as-a-bridge-to-decision-during-acute-decompensation-of-advanced-heart-failure
#15
Shelley A Hall, Nir Uriel, Sandra A Carey, Michelle Edens, Geoffrey Gong, Michele Esposito, Ryan O'Kelly, Shiva Annamalai, Nima Aghili, S Adatya, Navin K Kapur
BACKGROUND: Prognosis is poor for patients with decompensated advanced heart failure (HF) refractory to medical therapy. Evaluating candidacy for durable mechanical circulatory support (MCS), cardiac transplantation, or palliative care is complex, and time is often needed to stabilize the patient hemodynamically. The Impella 5.0 (Abiomed, Danvers, MA) is a minimally invasive axial-flow catheter capable of providing full temporary hemodynamic support. We report a multicenter series on the use of this device for bridge to decision (BTD) in decompensated advanced HF patients...
September 30, 2017: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29052786/tolvaptan-promotes-urinary-excretion-of-sodium-and-urea-a-retrospective-cohort-study
#16
Satoshi Minami, Takayuki Hamano, Hirotsugu Iwatani, Masayuki Mizui, Yoshiki Kimura, Yoshitaka Isaka
BACKGROUND: Tolvaptan (TLV) promotes aquaresis; however, little is known about its effect on solute excretion in chronic kidney disease (CKD). METHODS: We retrospectively studied CKD patients with decompensated heart failure (HF) or those with autosomal dominant polycystic kidney disease (ADPKD) receiving TLV. Patients with an increased urine volume of more than twice of daily variance were defined as "responders" in HF. We compared the ability of the urinary osmolality (U-OSM) change and urinary creatinine concentration ([U-Cr]) change to discriminate "responders"...
October 20, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29045285/milrinone-dosing-and-a-culture-of-caution-in-clinical-practice
#17
Luke Yong Zheng Chong, Kumar Satya, Bernard Kim, Robert Berkowitz
Milrinone is an invaluable agent in the treatment of end-stage heart failure patients who are refractory to optimal medical therapy. In addition to its use in acute decompensated heart failure, milrinone can also be employed as a home infusion therapy or a bridge to cardiac transplant. Concerns about its adverse effects, such as an increased risk of arrhythmias and hypotension, often limit the doses of milrinone used in clinical practice. In addition, milrinone is infrequently used or avoided entirely in patients with acute renal failure or end-stage renal disease since the drug is primarily cleared by renal excretion...
October 17, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/29044493/combining-echo-and-natriuretic-peptides-to-guide-heart-failure-care-in-the-outpatient-setting-a-position-paper
#18
REVIEW
Frank Lloyd Dini, Erberto Carluccio, Fabrizio Montecucco, Gian Marco Rosa, Paolo Fontanive
BACKGROUND: Chronic heart failure (HF) is a relevant and growing public health problem. Although the prognosis has recently improved, it remains a lethal disease, with a mortality that equals or exceeds that of many malignancies. Furthermore, chronic HF is costly, representing a large and growing drain on healthcare resources. METHODS: This narrative review is based on the material searched for and obtained via PubMed up to May 2017. The search terms we used were: "heart failure, echocardiography, natriuretic peptides" in combination with "treatment, biomarkers, guidelines"...
October 16, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29035000/use-of-sacubitril-valsartan-in-acute-decompensated-heart-failure-a-case-report
#19
Taison D Bell, Adrien J Mazer, P Elliott Miller, Jeffrey R Strich, Vandana Sachdev, Mary E Wright, Michael A Solomon
Refractory heart failure typically requires costly long-term, continuous intravenous inodilator infusions while patients await mechanical circulatory support or cardiac transplantation. The combined angiotensin receptor blocker-neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides. This therapy has been recommended as an alternative agent in patients with chronic heart failure with reduced ejection fraction and New York Heart Association class II-III symptoms...
October 16, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/29030210/continuous-cardiac-inotropes-in-patients-with-end-stage-heart-failure-an-evolving-experience
#20
Kasey Malotte, Agafe Saguros, Hunter Groninger
Heart failure experts recommend initiation of continuous inotrope therapy, such as milrinone or dobutamine, for clinically decompensating patients with stage D heart failure. Although originally intended to serve solely as a bridge to more definitive surgical therapies, more and more patients are receiving inotrope therapy for purely palliative purposes. In these cases, questions arise regarding care at the end of life. What criteria determine ongoing clinical benefit? Should the inotrope be continued until death? Should inotrope dosing be increased within recommended guidelines to improve symptoms? What is the role of inotropes in hospice care? Here, we describe such a case as a springboard to contemplate the evolving role of inotrope therapies and how hospice and palliative providers may interface with this rapidly developing face of advanced heart failure care...
October 10, 2017: Journal of Pain and Symptom Management
keyword
keyword
63090
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"